论文部分内容阅读
目的:探索保留膀胱手术+膀胱内灌注化疗+动脉灌注化疗治疗浸润性膀胱癌的临床疗效。方法:2003年5月～2012年2月,对经尿道膀胱肿瘤电切或膀胱部分切除后确诊为浸润性膀胱癌(T2N0M0)的56例保留膀胱的患者,给予动脉灌注化疗加膀胱灌注化疗。结果:56例患者均获得随访,随访6～98个月,平均36个月,53例(94.6%)患者无复发及转移,3例(5.4%)分别在术后6、8、12复发,复发患者均给予全膀胱切除术,无死亡病例,没有明显并发症。结论:保留膀胱手术后确诊的局限性浸润性膀胱癌的患者,采用经髂内动脉灌注化疗+膀胱内灌注化疗的联合治疗方法,能明显的提高疗效,有效地减少肿瘤的复发,显著的降低了静脉化疗的副作用,提高了患者的生活质量,患者易于接受,值得进一步探讨。
Objective: To explore the clinical curative effect of reserving bladder surgery + intravesical chemotherapy + arterial infusion chemotherapy for invasive bladder cancer. Methods: From May 2003 to February 2012, 56 patients with bladder preservation who had been diagnosed with invasive bladder cancer (T2N0M0) after transurethral resection of the bladder tumor or partial bladder resection were given intra-arterial infusion chemotherapy and intravesical chemotherapy. Results: Fifty-six patients were followed up for 6 to 98 months with an average of 36 months. No recurrence or metastasis was found in 53 patients (94.6%). Three patients (5.4% Recurrent cystectomy patients were given, no deaths, no significant complications. CONCLUSIONS: In patients with localized invasive bladder cancer diagnosed after bladder surgery, the combined treatment of intra-artial iliac arterial infusion chemotherapy and intravesical chemotherapy can significantly improve the efficacy and reduce the recurrence of the tumor effectively with a significant reduction The side effects of intravenous chemotherapy to improve the quality of life of patients, patients are easy to accept, it is worth further exploration.